The Weekly $385 Calls made a 22% move from 21.50-26.20. The Weekly $395’s fared even better, with a daily low of 11.60 giving way to a 17.02 close; good for up to 47% in profits.
There were even big-time chances on the longer term Calls we mentioned, for example, the October $420 Calls ranged from 17.36 all the way up to 24.60, a 42% rip.
We’ll continue to track the Call-side on ISRG as provided by a continued trend off of its recent relative bottom.
Solar Wind Energy tower, Inc. SWET
We tried to give our readers advance notice on SWET and the chart’s potential for a nice move up, first bringing it up on Friday, and focusing in again in yesterday morning’s report. We were happy to see things take a northerly turn to kick off the week, as the stock ran 18% intraday from .0193 and reaching .0227, a solid 23% increase from Friday’s low of .0185.
We still like the look of things with regard to the chart, and with oil & gas spiking it can provide a boost to solar plays like this one, as we’re now witnessing. We’ll keep SWET on our radar screens as the week progresses, and we wouldn’t be surprised to see further opportunities come down the pipe.
GW Pharmaceuticals, Inc GWPH
GWPH was a stock that we were tracking along with the large group of cannabis-related stocks earlier this year. On January 27th, we had it listed among several plays that we felt could provide continued opportunities, and over the past few months, it has become a real success-story for us.
Coming from the $50-range back in late January, the stock made an extremely nice move to the tune of roughly 65% up to the low $80’s.
After a period of consolidation in which it came all the way back down to find support at 41.86 (Apr 15th), and we’ve now seen it trend up once again, reaching 79.24 on Thursday, an added 89% increase. So the opportunities have certainly been present, and the stock is gapping up even higher in the pre-market on the heels of an apparently well-received PR released at 7am this morning.
We also want to radar the $80-85 Calls on the options side of things, to maximize our potential even further on this play.
LONDON, June 17, 2014 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW’s investigational cannabidiol (CBD) product candidate, Epidiolex(R), for a period of 12 weeks. >> FULL PR
Extended Watchlist:
DDD ($52-53 Calls), FST, WAVX, AGRX, GIGA, PNBK
